Collaboration for Accelerated Vaccine Development
Advancing CEPI's 100 Days Mission to Accelerate Vaccine Development
LenioBio, a trailblazer in rapid cell-free protein expression technologies, has embarked on a significant collaboration with ReciBioPharm. This partnership aims to enhance protein manufacturing capabilities and expedite vaccine production, a vital step in addressing global health challenges.
Expanding on Success
The collaboration is part of a broader expansion of LenioBio's initiatives, which received funding from CEPI (Coalition for Epidemic Preparedness Innovations). Their project highlights the speed and capacity of LenioBio's proprietary ALiCE® technology, specifically designed for producing vaccine-related proteins for clinical trials. The project's initial stages brought notable achievements, with LenioBio successfully demonstrating the technology's reliable protein production capabilities utilizing cell-free DNA formats.
Quality and Safety Assurance
As part of their commitment to excellence, LenioBio also developed innovative quality control assays to ensure product integrity and safety during the entire protein production process. These advancements are crucial as they lay the groundwork for ensuring high standards in vaccine development.
Leveraging ReciBioPharm's Expertise
Through this collaboration, LenioBio will leverage ReciBioPharm's extensive expertise in the development and manufacture of complex biologics. This strategic alliance aims to optimize the production of vaccine proteins at an increased scale using ALiCE®. The partnership is set to cultivate groundbreaking advancements in vaccine manufacturing, ultimately leading to more efficient processes.
Meeting Urgent Health Needs
André Goerke, CEO of LenioBio, emphasized the significance of collaborating with ReciBioPharm, stating, "This alliance takes us closer to realizing the goal of swift vaccine development, crucial in addressing emerging health threats." Transferring production capabilities to a leading contract development and manufacturing organization (CDMO) enables the team to respond to urgent medical needs effectively.
Technology Transfer and Growth
The collaboration will also facilitate technology transfer aimed at 10-liter scale protein production. This will support pre-clinical studies, marking a critical milestone in establishing ALiCE® technology in a large-scale manufacturing environment. Additionally, it sets the stage for future Good Manufacturing Practice (GMP) applications, ensuring vaccines and therapeutics move effectively through clinical trials.
A Vision for Rapid Development
Vikas Gupta, president of ReciBioPharm, remarked on the importance of this collaboration in advancing recombinant protein manufacturing. He noted that the innovative ALiCE® technology has the potential to significantly impact global health by accelerating the development of vital vaccines and biologics. The partnership aligns with ReciBioPharm's commitment to fostering innovation and expediting solutions for emerging health threats.
Evaluating Protein Quality
Looking to the future, LenioBio plans to conduct comprehensive evaluations of the quality of proteins produced using ALiCE® technology. This includes in vivo studies that focus on dosage and efficacy. Regulatory discussions will also be pivotal as the company positions ALiCE® as a transformative platform for rapidly developing protein medicines and decreasing the timeline for vaccines to reach clinical trials.
The 100 Days Mission Explained
The 100 Days Mission, led by CEPI and backed by global leaders, aims to drastically decrease the vaccine development timeline. The initiative demonstrated its effectiveness by shortening the development period for the initial licensed COVID-19 vaccines significantly. This mission holds the promise of preventing future outbreaks from transforming into global health crises.
About LenioBio
LenioBio is at the forefront of biotechnology, pioneering a revolutionary protein expression platform. With its ALiCE® technology, LenioBio enables researchers and biopharmaceutical manufacturers to streamline their protein discovery and production processes, enhancing the efficiency with which drugs are brought to patients in need.
About ReciBioPharm
ReciBioPharm, a division of Recipharm, specializes in contract development and manufacturing for advanced therapy medicinal products (ATMPs). Their CDMO capabilities span from pre-clinical stages to commercial development, encompassing modern biological modalities such as live viruses and viral vectors. With a team of seasoned experts, ReciBioPharm is dedicated to supporting the advancement of innovative therapies crucial for patient care worldwide.
Frequently Asked Questions
What is the main goal of the collaboration between LenioBio and ReciBioPharm?
The collaboration aims to enhance protein manufacturing capabilities and expedite the production of vaccines.
How does the ALiCE® technology contribute to vaccine development?
ALiCE® technology allows for the rapid production of vaccine-relevant proteins, facilitating quicker clinical trial processes.
What is the significance of the 100 Days Mission?
The 100 Days Mission seeks to significantly shorten the time required to develop vaccines, aiming to prevent future pandemics.
Who are the key players in the collaboration?
LenioBio and ReciBioPharm are the primary organizations involved, with LenioBio pioneering protein expression technology and ReciBioPharm providing manufacturing expertise.
What steps will be taken to ensure the quality of produced proteins?
LenioBio will conduct in vivo studies and regulatory discussions to ensure the efficacy and safety of proteins produced using ALiCE® technology.
